Table 1 Clinical characteristics of study subjects
Total (N = 209) | |
|---|---|
Age, years | 47.93 ± 13.10 |
Age group, n (%) | |
< 65 years | 183 (87.56) |
≥ 65 years | 26 (12.44) |
Sex, male, n (%) | 128 (61.24) |
Height, cm | 164.85 ± 8.80 |
Body Weight, kg | 61.73 ± 10.75 |
Allergy history, n (%) | 5 (2.39) |
Secondary transplantation, n (%) | 10 (4.78%) |
Primary cause of kidney failure, n (%) | |
Hypertension | 56 (26.79) |
Diabetes mellitus | 33 (15.79) |
Glomerulonephritis | 55 (26.32) |
Polycystic kidney disease | 11 (5.26) |
Others | 54 (25.84) |
Panel reactive antibody of recipients (%) | |
Class I | 6.35 ± 21.50 |
Class II | 5.89 ± 17.39 |
Type of donation, n (%) | |
Living donor | 132 (63.46) |
Deceased donor | 76 (36.54) |
Age of donors, years | 41.49 ± 13.16 |
Past general medical history, n (%)a | 141 (67.46%) |
Liver disease, n (%) | 13 (6.22%) |
Concomitant immunosuppressive medication, n (%)b | |
Monotherapy | 44 (21.05) |
Dual therapy | 140 (66.99) |
Triple therapy | 25 (11.96) |
Trough level of cyclosporine, ng/mL | |
Immunoassay | 72.84 ± 47.01 |
HPLC method | 100.18 ± 64.80 |
Trough level of tacrolimus, ng/mL | |
Immunoassay | 4.34 ± 1.77 |
HPLC method | 4.51 ± 3.25 |
Trough level of mycophenolic acid, ng/mL | |
HPLC method | 1.53 ± 0.86 |
Time between transplantation and the first administration of Rapamune, days, median (range) | median 909 (range: 9 to 10,816) |
< 6 months, n (%) | 28 (13.40) |
6 months to < 1 year, n (%) | 20 (9.57) |
1 year to < 5 years, n (%) | 94 (44.98) |
≥ 5 years, n (%) | 65 (31.10) |
Total administration period of Rapamune, days | median 182 (range: 4 to 971) |
< 6 months, n (%) | 96 (45.93) |
6 month to < 1 year, n (%) | 99 (47.37) |
≥ 1 year, n (%) | 14 (6.70) |
Daily dose of Rapamune, mg | 1.79 ± 0.68 |
< 2 mg, n (%) | 112 (53.59) |
2 mg, n (%) | 46 (22.01) |
> 2 mg, n (%) | 51 (24.40) |
Trough level of Rapamune, ng/mL | |
Immunoassay | 5.45 ± 2.59 |
HPLC method | 7.87 ± 4.24 |